ImmuCell (ICCC) Set to Announce Quarterly Earnings on Thursday

ImmuCell (NASDAQ:ICCC) will issue its quarterly earnings data after the market closes on Thursday, May 9th. Parties that are interested in participating in the company’s conference call can do so using this link.

ImmuCell (NASDAQ:ICCC) last announced its quarterly earnings results on Tuesday, February 27th. The biotechnology company reported ($0.15) earnings per share for the quarter. The firm had revenue of $5.10 million during the quarter. ImmuCell had a negative net margin of 33.05% and a negative return on equity of 21.79%.

ImmuCell Stock Performance

Shares of NASDAQ:ICCC opened at $5.01 on Thursday. The company has a market capitalization of $39.14 million, a price-to-earnings ratio of -6.67 and a beta of 0.59. The firm’s 50 day simple moving average is $5.16 and its 200 day simple moving average is $5.01. The company has a debt-to-equity ratio of 0.42, a current ratio of 2.73 and a quick ratio of 0.87. ImmuCell has a fifty-two week low of $4.26 and a fifty-two week high of $6.05.

ImmuCell Company Profile

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E.